Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
08 août 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Interim analysis results from two Phase 3 trials and topline results from one Phase 2 trial of AXS-05 anticipated in 4Q 2018 Phase 3 trial of AXS-07 in acute migraine anticipated to start in 4Q 2018 ...
Aegis Expands its International and US Intravail® Patent Portfolio on Multiple Fronts
02 août 2018 06h00 HE
|
Aegis Therapeutics LLC
SAN DIEGO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded European Patent No. EP2381773(B1) and Canadian Patent No. 2,748,268, providing fast...
Alder BioPharmaceuticals® Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine
29 juin 2018 08h30 HE
|
Alder BioPharmaceuticals, Inc.
- Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate eptinezumab’s robust efficacy is further improved at one year following third and fourth quarterly...
Alder BioPharmaceuticals® Presents New Six-Month Data for Eptinezumab Demonstrating Improvement in Efficacy in PROMISE 2 Phase 3 Trial for Chronic Migraine
29 juin 2018 08h30 HE
|
Alder BioPharmaceuticals, Inc.
- Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate 43% of patients receiving 300 mg of eptinezumab achieved a 75% or greater reduction of monthly...
Alder BioPharmaceuticals® to Present New Data Further Highlighting Eptinezumab’s Efficacy Profile for Migraine Prevention at American Headache Society Meeting
20 juin 2018 08h30 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., June 20, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Migraine Impacts Employers in both Health Care Spend and Lost Productivity Per Integrated Benefits Institute Study
13 juin 2018 07h34 HE
|
Integrated Benefits Insitute
San Francisco, June 13, 2018 (GLOBE NEWSWIRE) -- SAN FRANCISCO – June 13, 2018 – Employers bear more than the costs of medical treatments for employees who suffer with migraine—there are also...
Axsome Therapeutics Announces AXS-07 for the Treatment of Migraine
28 nov. 2017 07h00 HE
|
Axsome Therapeutics, Inc.
Incorporates new molecular entity for migraine and Axsome’s MoSEIC™ technology Potential for superior efficacy as compared to current treatments FDA Pre-IND meeting written guidance received Issued...
Alder BioPharmaceuticals® to Present at 29th Annual Piper Jaffray Healthcare Conference
22 nov. 2017 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today...
Alder BioPharmaceuticals® to Present at 26th Annual Credit Suisse Healthcare Conference
01 nov. 2017 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today...
Alder BioPharmaceuticals® to Host Conference Call to Discuss Third Quarter 2017 Financial and Operating Results
31 oct. 2017 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today...